[go: up one dir, main page]

WO1988007365A3 - Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic - Google Patents

Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic Download PDF

Info

Publication number
WO1988007365A3
WO1988007365A3 PCT/US1988/001096 US8801096W WO8807365A3 WO 1988007365 A3 WO1988007365 A3 WO 1988007365A3 US 8801096 W US8801096 W US 8801096W WO 8807365 A3 WO8807365 A3 WO 8807365A3
Authority
WO
WIPO (PCT)
Prior art keywords
carrier
endothelial
vascular
diagnostic
endothelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1988/001096
Other languages
English (en)
Other versions
WO1988007365A1 (fr
WO1988007365A2 (fr
Inventor
David F Ranney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25671864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1988007365(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to DE3881881T priority Critical patent/DE3881881T3/de
Priority to AT88903702T priority patent/ATE90554T1/de
Priority to EP88903702A priority patent/EP0352295B2/fr
Priority to CA000565119A priority patent/CA1324080C/fr
Publication of WO1988007365A1 publication Critical patent/WO1988007365A1/fr
Publication of WO1988007365A2 publication Critical patent/WO1988007365A2/fr
Publication of WO1988007365A3 publication Critical patent/WO1988007365A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Préparation et expérimentation in vivo de revêtements de surface et de matériaux matriciels qui, lorsqu'ils contiennent les supports de medicaments et d'agents de diagnostic ou qu'ils leurs sont appliqués et sont administrés de façon à permettre un accès vasculaire efficace, provoquent la reconnaisssance par le support de substances déterminantes présentes sur un endothélium normal ou affecté localement, et entraînent les effets in vivo suivants: 1) enveloppement rapide, partiel ou total du support de médicament (ou d'agent de diagnostic); 2) séquestration du support et protection rapide (2 minutes) de l'agent encapsulé de l'épuration vasculaire sanguine lorsque la poche endothéliale qui enveloppe le support est encore en train d'invaginer le compartiment vasculaire; 3) accélération du transport du support à travers l'endothelium vasculaire ou les structures sub-endothéliales vers l'interstice; et 4) amélioration de l'efficacité de migration du médicament (oude l'agent de diagnostic) à travers les barrières endothéliales ou sub-endothéliales, ce qui permet de réduire la dose totale de medicament requise pour obtenir l'effet désiré par rapport à la dose correspondante en agents habituels. Une absorption tissulaire analogue est obtenue pour la migration transepithéliale dans les poumons, la vessie et les intestins.
PCT/US1988/001096 1987-04-01 1988-03-30 Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic Ceased WO1988007365A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE3881881T DE3881881T3 (de) 1987-04-01 1988-03-30 Bioadhäsiver arzneiträger zur endothelialen und epithelialen aufnahme und läsionalen lokalisierung therapeutischer und diagnostischer stoffe.
AT88903702T ATE90554T1 (de) 1987-04-01 1988-03-30 Bioadhaesiver arzneitraeger zur endothelialen und epithelialen aufnahme und laesionalen lokalisierung therapeutischer und diagnostischer stoffe.
EP88903702A EP0352295B2 (fr) 1987-04-01 1988-03-30 Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic
CA000565119A CA1324080C (fr) 1987-04-01 1988-04-26 Vecteurs de medicaments bioadhesifs pour absorption endotheliale et epitheliale et transport de l'agent therapeutique ou diagnostic jusqu'a la lesion

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US033,432 1987-04-01
US07/033,432 US4925678A (en) 1987-04-01 1987-04-01 Endothelial envelopment drug carriers
CA000565119A CA1324080C (fr) 1987-04-01 1988-04-26 Vecteurs de medicaments bioadhesifs pour absorption endotheliale et epitheliale et transport de l'agent therapeutique ou diagnostic jusqu'a la lesion

Publications (3)

Publication Number Publication Date
WO1988007365A1 WO1988007365A1 (fr) 1988-10-06
WO1988007365A2 WO1988007365A2 (fr) 1988-10-06
WO1988007365A3 true WO1988007365A3 (fr) 1988-11-17

Family

ID=25671864

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1988/001096 Ceased WO1988007365A2 (fr) 1987-04-01 1988-03-30 Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic

Country Status (8)

Country Link
US (1) US4925678A (fr)
EP (1) EP0352295B2 (fr)
JP (1) JP2886171B2 (fr)
AT (1) ATE90554T1 (fr)
AU (1) AU607494B2 (fr)
CA (1) CA1324080C (fr)
DE (1) DE3881881T3 (fr)
WO (1) WO1988007365A2 (fr)

Families Citing this family (163)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
US5807832A (en) * 1987-06-09 1998-09-15 Biotech Australia Pty Limited Oral delivery of biologically active substances bound to vitamin B12
EP0361960A3 (fr) * 1988-09-29 1992-01-02 RANNEY, David F. Procédé et compositions pour la production d'images par résonance magnétique
US5213788A (en) * 1988-09-29 1993-05-25 Ranney David F Physically and chemically stabilized polyatomic clusters for magnetic resonance image and spectral enhancement
US5260050A (en) * 1988-09-29 1993-11-09 Ranney David F Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5527527A (en) * 1989-09-07 1996-06-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
US5182107A (en) * 1989-09-07 1993-01-26 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5154924A (en) * 1989-09-07 1992-10-13 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
JP2653245B2 (ja) * 1989-11-27 1997-09-17 日本新薬株式会社 脂肪乳剤
US5227372A (en) * 1990-03-07 1993-07-13 Children's Medical Center Corporation Method for retaining ophthalmological agents in ocular tissues
IN172208B (fr) * 1990-04-02 1993-05-01 Sint Sa
USRE39146E1 (en) 1990-04-02 2006-06-27 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US6989141B2 (en) 1990-05-18 2006-01-24 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US6613306B1 (en) 1990-04-02 2003-09-02 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US7083778B2 (en) 1991-05-03 2006-08-01 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
JPH0776175B2 (ja) * 1990-04-26 1995-08-16 サイトアーレクス・コーポレーシヨン 損傷されたかまたは病気になった組織の局所的処置用の組成物および方法
US5216130A (en) * 1990-05-17 1993-06-01 Albany Medical College Complex for in-vivo target localization
IE921050A1 (en) * 1991-04-02 1992-10-07 Biotech Australia Pty Ltd Oral delivery systems for microparticles
AU707085B2 (en) * 1991-04-02 1999-07-01 Access Pharmaceuticals Australia Pty Limited Oral delivery systems for microparticles
US5705178A (en) * 1991-05-31 1998-01-06 Gliatech, Inc. Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
GB9119762D0 (en) * 1991-09-16 1991-10-30 Filler Aaron G Particulate agents for nmt
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
FR2687071B1 (fr) * 1992-02-10 1995-06-23 Exsymol Sa Vecteur pour principe(s) actif(s) therapeutique(s) ou cosmetique(s) a usage externe et composition therapeutique ou cosmetique comprenant un tel vecteur.
US5474765A (en) * 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
AU4693093A (en) * 1992-07-27 1994-02-14 Haemacure Biotech Inc. Biocompatible surgical implant
WO1994003501A1 (fr) * 1992-08-05 1994-02-17 Meito Sangyo Kabushiki Kaisha Composite de petit diametre constitue de carboxypolysaccharide hydrosoluble et d'oxyde de fer magnetique
WO1994008564A1 (fr) * 1992-10-08 1994-04-28 Valery Yu Alakhov Compositions d'agents antineoplasiques incorpores dans des micelles
US5362425A (en) * 1992-10-22 1994-11-08 Technology Unlimited, Inc. Organic oil spray-drying techniques
US5916596A (en) * 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
DE69433723T3 (de) * 1993-02-22 2008-10-30 Abraxis Bioscience, Inc., Los Angeles Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
US6528067B1 (en) 1993-02-22 2003-03-04 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
EP0684814B1 (fr) * 1993-02-22 1998-06-17 Alza Corporation Compositions destinees a l'apport oral d'agents actifs
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5997904A (en) * 1993-02-22 1999-12-07 American Bioscience, Inc. Total nutrient admixtures as stable multicomponent liquids or dry powders and methods for the preparation thereof
EP0689430B1 (fr) * 1993-03-17 1997-08-13 Silica Gel Ges.M.B.H Particules supraparamagnetiques, leur procede de production et leur utilisation
GB9312315D0 (en) * 1993-06-15 1993-07-28 Poston Robin Leukocyte adhesion assay
DE69427251T2 (de) * 1993-07-27 2001-10-31 Terumo K.K., Tokio/Tokyo Verabreichungssystem für Arzneistoffe
ATE281183T1 (de) * 1993-07-30 2004-11-15 Alliance Pharma Stabilisierte mikrogasblaeschen-zusammensetzungen für echografie
US5798091A (en) 1993-07-30 1998-08-25 Alliance Pharmaceutical Corp. Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement
US5633003A (en) * 1994-03-31 1997-05-27 Cantor; Jerome O. Use of intratracheally administered hyaluronic acid to ameliorate emphysema
AUPM572294A0 (en) * 1994-05-18 1994-06-09 Vaccine Technologies Pty. Ltd. Delivery vehicle for bioactive molecule
EP0774970A4 (fr) * 1994-08-10 2000-02-02 Roderick T Coward Methode d'utilisation de l'acide hyaluronique pour la detection, la localisation et le diagnostic de tumeurs
FR2723849B1 (fr) 1994-08-31 1997-04-11 Biovector Therapeutics Sa Procede pour augmenter l'immunogenicite, produit obtenu et composition pharmaceutique
US5540909A (en) * 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
WO1996041236A1 (fr) * 1995-06-07 1996-12-19 The Regents Of The University Of California Microelements a usage therapeutique et leurs procedes d'obtention et d'utilisation
US6107102A (en) * 1995-06-07 2000-08-22 Regents Of The University Of California Therapeutic microdevices and methods of making and using same
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US6106866A (en) * 1995-07-31 2000-08-22 Access Pharmaceuticals, Inc. In vivo agents comprising cationic drugs, peptides and metal chelators with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles, including tumor sites
US6218594B1 (en) 1995-11-08 2001-04-17 University Of South Florida Guinea pig model for leiomyomas
JP4280304B2 (ja) 1996-01-10 2009-06-17 ジーイー・ヘルスケア・アクスイェ・セルスカプ 造影剤
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
ATE298582T1 (de) 1996-04-19 2005-07-15 Alpha Therapeutic Corp Verfahren zur inaktivierung von viren und lyophilisierung von blutproteinen
EP1369111A1 (fr) * 1996-10-03 2003-12-10 Hermes Biosciences, Inc. Microparticules hydrophiles et leurs procédés de préparation
US6096291A (en) * 1996-12-27 2000-08-01 Biovector Therapeutics, S.A. Mucosal administration of substances to mammals
CA2302569A1 (fr) * 1997-09-05 1999-03-18 Maruho Kabushikikaisha Preparation en nanocapsule pour le traitement de maladies intraarticulaires
US6489306B2 (en) 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6338834B1 (en) 1998-04-30 2002-01-15 The Curators Of The University Of Missouri Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma
US6391861B1 (en) 1998-05-14 2002-05-21 The Trustees Of Columbia University In The City Of New York Method for the prevention of tissue elastic fiber injury
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
AU4994899A (en) 1998-07-13 2000-02-01 University Of South Florida Modulation of the phospholipase a2 pathway as a therapeutic
WO2000006696A2 (fr) * 1998-07-30 2000-02-10 University Of South Florida Procede de modulation du fonctionnement de facteurs de transcription
US6780397B2 (en) 1998-09-01 2004-08-24 Curators Of The University Of Missouri Biomolecule conjugation strategy using novel water-soluble phosphine-based chelating agents
US6379691B1 (en) 1998-09-29 2002-04-30 Medtronic/Ave, Inc. Uses for medical devices having a lubricious, nitric oxide-releasing coating
US6299980B1 (en) 1998-09-29 2001-10-09 Medtronic Ave, Inc. One step lubricious coating
US6409987B1 (en) 1999-04-07 2002-06-25 Intimax Corporation Targeted agents useful for diagnostic and therapeutic applications
US6638974B1 (en) 1999-04-09 2003-10-28 University Of South Florida Ascorbyl esters for the treatment of cancer
US6787318B1 (en) * 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
US7655423B2 (en) * 1999-06-14 2010-02-02 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
IL147112A0 (en) * 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
WO2001041756A2 (fr) 1999-12-02 2001-06-14 University Of South Florida Methode et composition permettant le traitement des lesions neuronales induites par ischemie-reperfusion
AU2001264817A1 (en) * 2000-05-23 2001-12-17 Exhale Therapeutics, Inc. Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans
US20020022594A1 (en) * 2000-07-11 2002-02-21 Ping Dou Bax fragment induced tumor cell death
US6803060B2 (en) 2000-09-07 2004-10-12 Joe Reyes Composition to boost libido
CA2950109C (fr) * 2000-10-27 2019-02-19 John W. Hadden Immunotherapie vaccinale pour patients immunodeprimes
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070025958A1 (en) 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
US7172770B2 (en) * 2001-02-19 2007-02-06 Board Of Regents, The University Of Texas System Mesoporous compositions for use in drug delivery
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
AU2002342151B2 (en) * 2001-10-26 2007-07-19 Immuno-Rx, Inc. Immunotherapy for reversing immune suppression
DE60304945T2 (de) * 2002-07-16 2007-01-04 Seiko Epson Corp. Mikrokapselhaltige Zusammensetzung für elektrophoretische Anzeigen
AU2003284968A1 (en) * 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
WO2005021065A2 (fr) * 2003-08-29 2005-03-10 New York University Administration indirecte de facteurs de croissance dans le systeme nerveux central
EP1663283B1 (fr) * 2003-09-12 2012-05-23 University of Colorado Glutamine pour le traitement de lesion
WO2005059100A2 (fr) * 2003-12-12 2005-06-30 New York University Procedes et compositions se rapportant a la cystatine c
DE602005025347D1 (de) 2004-01-30 2011-01-27 Quark Pharmaceuticals Inc Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
CN101123994B (zh) 2004-08-16 2012-11-14 夸克医药公司 Rtp801的抑制剂的治疗性用途
HUE030844T2 (en) 2004-09-28 2017-06-28 Quark Pharmaceuticals Inc Oligoribonucleotides and methods of their application for the treatment of allopathy, acute renal failure and other diseases
DE112005002270T5 (de) * 2004-09-28 2007-08-30 Osaka University Dreidimensionales Führungssystem und Verfahren, und Arznei-Zuführungssystem
US8541177B2 (en) 2006-01-13 2013-09-24 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
DOP2007000015A (es) 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
US20080260678A1 (en) * 2006-10-10 2008-10-23 University Of Colorado Molecular band-aid
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US8729121B2 (en) 2007-06-25 2014-05-20 Adhezion Biomedical, Llc Curing accelerator and method of making
WO2009001359A2 (fr) 2007-06-27 2008-12-31 Quark Pharmaceuticals, Inc. Compositions et procédés d'inhibition de l'expression de gènes pro-apoptotiques
RU2487716C2 (ru) 2007-10-03 2013-07-20 Кварк Фармасьютикалс, Инк. Новые структуры малых интерферирующих рнк (sirna)
EP2742875B1 (fr) * 2007-11-14 2016-02-24 Adhezion Biomedical, LLC Adhésifs tissulaires cyanocarylates
US8486528B2 (en) * 2008-01-22 2013-07-16 Gwangju Institute Of Science And Technology Temperature-sensitive nano-carriers
EP2106791A1 (fr) 2008-03-31 2009-10-07 Biotempt B.V. Glutamine ou dipeptide contenant de la glutamine avec une posologie spécifique pour le traitement des inflammations
US8198344B2 (en) 2008-06-20 2012-06-12 Adhezion Biomedical, Llc Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator
US8293838B2 (en) * 2008-06-20 2012-10-23 Adhezion Biomedical, Llc Stable and sterile tissue adhesive composition with a controlled high viscosity
US20110117047A1 (en) 2008-06-23 2011-05-19 Adhezion Biomedical, Llc Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
US8609128B2 (en) * 2008-10-31 2013-12-17 Adhezion Biomedical, Llc Cyanoacrylate-based liquid microbial sealant drape
US8652510B2 (en) 2008-10-31 2014-02-18 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US9254133B2 (en) 2008-10-31 2016-02-09 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US20110288155A1 (en) 2008-12-18 2011-11-24 Elena Feinstein Sirna compounds and methods of use thereof
CA2756574C (fr) 2009-03-26 2020-01-28 Henry Ford Health System Thymosine beta-4 destinee au traitement de blessure neuronale en myelinisant les neurones endommages
US8637482B2 (en) 2009-06-08 2014-01-28 Quark Pharmaceuticals, Inc. Methods for treating chronic kidney disease
KR20120102630A (ko) 2009-11-26 2012-09-18 쿠아크 파마수티칼스 인코퍼레이티드 말단 치환체를 포함하는 에스아이 알엔에이 화합물
KR101692063B1 (ko) * 2009-12-09 2017-01-03 닛토덴코 가부시키가이샤 hsp47 발현의 조절
WO2011072091A1 (fr) 2009-12-09 2011-06-16 Quark Pharmaceuticals, Inc. Méthodes et compositions utilisées pour le traitement de maladies, d'affections ou de lésions du snc
WO2011084193A1 (fr) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Composés oligonucléotidique comportant des extrémités sortantes non nucléotidiques
CA2827401A1 (fr) 2010-02-22 2011-08-25 Health Enhancement Products, Inc. Agents et mecanismes de traitement de l'hypercholesterolemie
US9309019B2 (en) 2010-05-21 2016-04-12 Adhezion Biomedical, Llc Low dose gamma sterilization of liquid adhesives
SG186438A1 (en) 2010-06-24 2013-01-30 Quark Pharmaceuticals Inc Double stranded rna compounds to rhoa and use thereof
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
SG190412A1 (en) 2010-12-06 2013-06-28 Quark Pharmaceuticals Inc Double stranded oligonucleotide compounds comprising threose modifications
CN103562387A (zh) 2011-03-03 2014-02-05 夸克医药公司 Toll样受体途径的寡核苷酸调剂
KR101937498B1 (ko) 2011-03-03 2019-04-10 쿠아크 파마수티칼스 인코퍼레이티드 폐 질환 및 손상을 치료하기 위한 조성물 및 방법
WO2013003697A1 (fr) 2011-06-30 2013-01-03 Trustees Of Boston University Méthode de régulation de croissance tumorale, d'angiogenèse et de métastase à l'aide du récepteur 1 riche en proline et contenant une immunoglobuline (igpr-1)
US20140323549A1 (en) 2011-11-08 2014-10-30 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
EP2797632A1 (fr) 2012-01-01 2014-11-05 QBI Enterprises Ltd. Particules ciblant endo180 pour l'administration sélective d'agents thérapeutiques et diagnostiques
WO2013106494A1 (fr) 2012-01-12 2013-07-18 Quark Pharmaceuticals, Inc. Polythérapie destinée au traitement de troubles de l'audition et de l'équilibre
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
PL2854841T3 (pl) 2012-06-04 2017-08-31 Diamedica Inc. Izoformy glikozylacji ludzkiej kalikreiny tkankowej 1
PT2864360T (pt) 2012-06-25 2018-01-05 The Brigham And Women`S Hospital Inc Terapêuticas dirigidas ao alvo
CN104619844A (zh) 2012-09-12 2015-05-13 夸克制药公司 靶向p53的双链寡核苷酸分子及其使用方法
WO2014043291A1 (fr) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Composés d'acide nucléique double brin
AU2013315524B2 (en) 2012-09-12 2019-01-31 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
EP2934540B1 (fr) 2012-12-24 2023-08-02 Neurogastrx, Inc. Méthodes de traitement d'affections du tractus digestif
MX2015011846A (es) 2013-03-12 2016-09-27 Massachusetts Gen Hospital Proteinas de sustancia de inhibicion mulleriana (mis) modificadas y sus usos para el tratamiento de enfermedades.
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
WO2014142938A1 (fr) * 2013-03-15 2014-09-18 Aihol Corporation Formulation pharmaceutique contenant un glycosaminoglycane
WO2014201372A1 (fr) 2013-06-13 2014-12-18 Health Enhancement Products, Inc. Composés et procédés pour affecter la sécrétion des cytokines
WO2015020960A1 (fr) 2013-08-09 2015-02-12 Novartis Ag Nouveaux polynucléotides longs arn non codants (arn lnc)
EP3079712B1 (fr) 2013-12-11 2022-02-02 The General Hospital Corporation Utilisation de protéines d'hormone anti-mullerienne (amh) pour la contraception et la préservation de la réserve ovarienne
US9421297B2 (en) 2014-04-02 2016-08-23 Adhezion Biomedical, Llc Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
WO2015200369A1 (fr) 2014-06-24 2015-12-30 Neurogastrx, Inc. Promédicaments de métopimazine
CA3011687A1 (fr) 2015-02-16 2016-08-25 Zivo Bioscience, Inc. Procedes de modulation de reponses immunitaires et inflammatoires par le biais de l'administration d'une biomasse algale
CN109414053A (zh) 2016-02-16 2019-03-01 齐沃生物科学股份有限公司 经由给予源自藻类的补充物的动物营养支持
KR20190122706A (ko) 2017-03-09 2019-10-30 다이어메디카 인코포레이티드 조직 칼리크레인 1의 투약 형태
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3922720A1 (fr) 2020-06-09 2021-12-15 Universidad de Murcia Thérapie pour empêcher un remodelage cardiaque indésirable après un infarctus aigu du myocarde
US20220265582A1 (en) 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
US11801256B2 (en) 2021-06-08 2023-10-31 Universitätsspital Basel Antidepressant-psilocybin co-treatment to assist psychotherapy

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1516348A (en) * 1974-09-18 1978-07-05 Pharma Soc Of Victoria Injectable compositions
GB2041517A (en) * 1979-01-09 1980-09-10 Fuji Photo Film Co Ltd Material and process for immunological assay
EP0087786A1 (fr) * 1982-02-28 1983-09-07 Yeda Research And Development Company, Ltd. Perles d'agarose et de polyaldéhydes, procédé pour leur préparation et leur usage
CA1168150A (fr) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Conjugats d'albumine et d'agents therapeutiques
EP0167825A2 (fr) * 1984-06-08 1986-01-15 Dr. Rentschler Arzneimittel GmbH & Co. Nanobilles lipidiques comme véhicule pour médicaments destinés à l'administration orale
GB2185397A (en) * 1986-01-17 1987-07-22 Cosmas Damian Ltd Drug delivery system
EP0240424A1 (fr) * 1986-03-28 1987-10-07 Universite De Rennes I Nanoparticules à base de polymère ou copolymère méthacrylique, procédé de préparation, et application comme vecteur de médicament

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2374910A1 (fr) * 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
US4182330A (en) * 1977-07-25 1980-01-08 Alza Corporation Means for administering amphipathic medicament
CS216992B1 (en) * 1980-07-21 1982-12-31 Miroslav Stol Composite polymere material for the biological and medicinal utilitation and method of preparation thereof
JPS57130914A (en) * 1981-02-04 1982-08-13 Agency Of Ind Science & Technol Prolongation of activity retention
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
SE8201972L (sv) * 1982-03-29 1983-09-30 Gambro Lundia Ab Magnetiskt paverkbara kristalliserade kolhydrat sferer eller partiklar att anvendas tillsammans med bioadsorberande material
US4624846A (en) * 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4568536A (en) * 1985-02-08 1986-02-04 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1516348A (en) * 1974-09-18 1978-07-05 Pharma Soc Of Victoria Injectable compositions
GB2041517A (en) * 1979-01-09 1980-09-10 Fuji Photo Film Co Ltd Material and process for immunological assay
CA1168150A (fr) * 1981-12-18 1984-05-29 The Governors Of The University Of Alberta Conjugats d'albumine et d'agents therapeutiques
EP0087786A1 (fr) * 1982-02-28 1983-09-07 Yeda Research And Development Company, Ltd. Perles d'agarose et de polyaldéhydes, procédé pour leur préparation et leur usage
EP0167825A2 (fr) * 1984-06-08 1986-01-15 Dr. Rentschler Arzneimittel GmbH & Co. Nanobilles lipidiques comme véhicule pour médicaments destinés à l'administration orale
GB2185397A (en) * 1986-01-17 1987-07-22 Cosmas Damian Ltd Drug delivery system
EP0240424A1 (fr) * 1986-03-28 1987-10-07 Universite De Rennes I Nanoparticules à base de polymère ou copolymère méthacrylique, procédé de préparation, et application comme vecteur de médicament

Also Published As

Publication number Publication date
EP0352295A1 (fr) 1990-01-31
AU607494B2 (en) 1991-03-07
AU1627588A (en) 1988-11-02
US4925678A (en) 1990-05-15
CA1324080C (fr) 1993-11-09
JP2886171B2 (ja) 1999-04-26
ATE90554T1 (de) 1993-07-15
EP0352295B1 (fr) 1993-06-16
EP0352295B2 (fr) 1996-04-10
WO1988007365A2 (fr) 1988-10-06
JPH04504404A (ja) 1992-08-06
DE3881881D1 (de) 1993-07-22
DE3881881T2 (de) 1993-12-16
DE3881881T3 (de) 1997-06-05

Similar Documents

Publication Publication Date Title
WO1988007365A3 (fr) Support de medicaments a bio-adhesion pour absorption endotheliale et epitheliale et localisation d'agents therapeutiques et de diagnostic
US5814599A (en) Transdermal delivery of encapsulated drugs
ES2056832T3 (es) Un vehiculo de liberacion para un ingrediente activo.
DE69010336D1 (de) Pharmazeutische zusammensetzung zum abnehmen.
CO5261582A1 (es) Composiciones de valdecoxib
Parsons et al. Initial fall of plasma calcium after intravenous injection of parathyroid hormone
HK1044290A1 (zh) X射線引導的藥物輸送
EP2298310A3 (fr) Inhibiteur thérapeutique de cellules de muscles vasculaires lisses
CA2382143A1 (fr) Procede, reactif et cartouche d'essai destines a determiner le temps de coagulation
Taal et al. Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice
SK42395A3 (en) Pharmaceutical agent for treatment or prevention of insulin-dependent diabetes mellitus, a method of producing and use thereof
Vander Els Sarcoidosis and IFN-alpha treatment
Pattanapanyasat et al. Effect of orally active hydroxypyridinone iron chelators on human lymphocyte function
Jewell et al. Heparin and ethyl biscoumacetate in prevention of experimental venous thrombosis
Weide et al. Study of immune function of cancer patients influenced by supplemental zinc or selenium-zinc combination
Lupera et al. Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer
Yamaoka et al. The antitumor effects of human lymphoblastoid interferon on human renal cell carcinoma in athymic nude mice
FI885797A7 (fi) Peptidejä, menetelmä niiden valmistamiseksi, niiden käyttö vasta-aineiden valmistamiseksi, sekä näiden käyttö ihmisen veren PAI-1-aktiivisuuden estämiseksi
McCue et al. A proposed short form of the Luria-Nebraska Neuropsychological Battery oriented toward assessment of the elderly.
Zakhireh et al. Unusually high occurrence of drug reactions with nafcillin
Shah et al. Development and clinical evaluation of a verapamil transdermal delivery system
Domb et al. Methotrexate polymer implant for the treatment of head and neck cancer
Petrilli et al. Single-dose actinomycin-D treatment for nonmetastatic gestational trophoblastic disease
Hoehne et al. Comparison of epinephrine excretion after aerosol and subcutaneous administration
RU2032424C1 (ru) Способ лечения лучевой лейкопении

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CH DE DK FI GB HU JP KP KR LK LU MC MG MW NL NO RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1988903702

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1988903702

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1988903702

Country of ref document: EP